Portage Biotech, Inc.

Adenosine antagonists market growth driven by R&D in neurodegenerative diseases, oncology, and cardiovascular disorders. Innovations in formulation and delivery systems enhance efficacy and safety, increasing adoption. Key companies include Arcus Biosciences, Corvus Pharmaceuticals, Portage Biotech, Palobiofarm, iTeos Therapeutics. Promising drugs like Etrumadenant, Ciforadenant, PORT-6, and Inupadenant are in various clinical trial phases.

Kronos Bio discontinues istisociclib development due to safety concerns, plans strategic alternatives to maximize shareholder value, and explores partnerships for preclinical assets KB-9558 and KB-7898.